# Efficacy and Safety of Standard of Care Plus Durvalumab in Patients With Limited Disease Small Cell Lung Cancer (DOLPHIN)

> **NCT04602533** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Michael Hopp** · enrollment: 105 (actual)

## Conditions studied

- Small Cell Lung Cancer Limited Stage

## Interventions

- **DRUG:** Durvalumab
- **DRUG:** standard of care

## Key facts

- **NCT ID:** NCT04602533
- **Lead sponsor:** Michael Hopp
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2020-12-21
- **Primary completion:** 2026-12-31
- **Final completion:** 2026-12-31
- **Target enrollment:** 105 (ACTUAL)
- **Last updated:** 2026-02-27

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04602533

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04602533, "Efficacy and Safety of Standard of Care Plus Durvalumab in Patients With Limited Disease Small Cell Lung Cancer (DOLPHIN)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04602533. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*